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S182 Oral Presentations3). Fifteen patients had improvement in, or correction of, their un-
derlying PIDD. Although these results are preliminary, our early ex-
perience suggests that outcomes can be improved in high-risk
patients with PIDD by using a modified nonmyeloablative
conditioning regimen and by selecting marrow as the source of he-
matopoietic cells. We observed stable donor engraftment in most
cases, an acceptable TRM, a low incidence of chronic GVHD, and
correction of underlying disease processes.76
MEGADOSES OF HAPLOCOMPATIBLE RELATED CD341 CELLS UTILIZING
CLINIMACS-BASED SELECTIONWITH A FIXED CD31 DOSE IN PEDIATRIC
PATIENTS IS SAFE AND EFFECTIVE
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Many patients lack an HLA-matched donor. We evaluated
whether the use of a fixed dose of CD31 cells with megadoses of
CD341 cells from Haplocompatible related donors (HRDs) would
be associated with good outcomes in children.
From 2002 to 2010, we performed a prospective Phase II trial uti-
lizing the CliniMACs (Miltenyi Biotec, Bisley, UK) system to per-
form CD341 cell selection of PBSC from HRDs in 21 pediatric
patients (median age 6.4 yrs, range 1.4-20.5 yrs). 15 patients had a he-
matologicmalignancy (AML/MDS, n5 9; ALL, n5 4; CML, n5 1;
JMML, n 1), 6 patients had a non-malignant condition (Bone Mar-
row Failure, n 5 3; HLH, n 3). Conditioning was TBI 1200 cGy
(200 cGy bid on Days -9 to -7), Thiotepa (5 mg/kg/dose bid on
Day -6), Fludarabine (40mg/m2/dose onDays -6 to -2), andThymo-
globulin (0.5 mg/kg on Day -5, 1 mg/kg on Days -4 to -2). Patients
received a median of 20  106/kg (range: 11-33  106/kg) CD341
cells with 3  104/kg CD31 cells/kg. Events were: graft failure, re-
lapse, and TRM. Statistics were performed using SPSS 16.0. EFS
was estimated using the Kaplan-Meier method.
Engraftment occurred in all but 2 patients (90%; 95% CI, 70-
99%), both with AML/MDS. Relapse occurred in 3 of 15 patients
(20%; 95% CI, 6-46%) at a median of 3.7 months (range: 1.3-12.4
months) post-HCT. All 5 patients eventually expired, despite 2nd
HRD HCT for 4 patients. One or more planned DLI (3  104
CD31 cells/kg) were administered to 11 patients to enhance immu-
nologic recovery. Grade I-II aGVHD was seen in 9 of 19 evaluable
patients (47%; 95% CI, 27-68%). There was no Grade III-IV
aGVHD. cGVHD was seen in 6 of 17 evaluable patients (35%;
95%CI, 17-59%). Infections (Sepsis &Mucor) resulted in the death
of 2 patients (10%; 95% CI, 1-30%) at 11 & 22 months post-HCT;
both were being treated for cGVHD. For all patients, the est. 2-year
EFS was 61% (95% CI, 49-73%). Patients with non-malignant dis-
eases had an est. 2-year EFS of 100% (95% CI, 56-100%). Patients
with malignancy in remission (n 9) had an est. 2-year EFS of 64%
(95% CI, 47-80%), while those not in remission (n 6) had an est.
2-year EFS of only 22% (95% CI, 3-41%). Median follow-up of
survivors was 34 months (range: 3-103 months).
Megadose CD341 cells with a fixed CD31 cell dose from HRDs
resulted in outcomes similar to those seen with other alternative-
donor stem cell sources. For pediatric patients with non-malignant
diseases or those transplanted in remission, outcomes were excellent.77
LUNG BIOPSY IN CHILDREN POST HEMATOPOIETIC STEM CELL TRANS-
PLANTATION
Craig-Barnes, H.A., Schechter, T., Doyle, J., Gassas, A. The Hospital for
Sick Children, Toronto, ON, Canada
Introduction: Pulmonary complications are common post hemato-
poietic stem cell transplantation (HSCT). Lung biopsies are invasive
procedures and their utility in the management of care of these pa-
tients is uncertain. This study aims to determine whether the diagno-
ses provided by lung biopsies change the management of care in
a pediatric HSCT patient population.Methods: We retrospectively reviewed charts from patients who
had a lung biopsy after a HSCT at The Hospital for Sick Children
in Toronto, Canada. The results of the lung biopsies were correlated
with the clinical management pre- and post-biopsy.
Results: From January 2000 to June 2010, 918 patients received
HSCT (allogeneic 476, autologus 442). A total of 59 biopsies
were performed in 48 patients (ages 6 months -17 years). Of the
48 patients, 32 patients received allo HSCT (20- malignant and
12- non-malignant) and 16 patients received auto HSCT. Biopsies
were open lung biopsies via a thoracotomy (38), thoracoscopic (9),
and percutaneous needle biopsy (12). The median time from
HSCT to biopsy was 3 months (range 7 days – 50 months). The
primary diagnosis from the biopsies was lung damage (vasculop-
athy, type II pneumocyte hyperplasia) attributed to drug or radia-
tion toxicity in 15 patients (25%). This was followed by recurrence
or metastasis of the primary malignant disease in 13 (22%), diffuse
alveolar damage in 10 (17%), interstitial inflammation in 7 (12%),
confirmed infection in 5 (8%), interstitial pneumonitis in 3 (5%),
BO(OP) in 2 (3%), ARDS in 1 (2%), pneumonia without an organ-
ism in 1(2%), pulmonary alveolar protienosis in 1 (2%) and nega-
tive findings in 1 patient (2%). Apart from the patients with
recurrent malignant disease results on biopsy, there were no major
changes in patients’ management of care after the lung biopsy.
Thirty-three patients died after the lung biopsy (68.75%) at a me-
dian of 1 month (range 1 day – 55 months). Cause of death in these
patients was primarily respiratory failure in 16 (48%) followed by
progression of malignant disease in 12 (36%), cardiac arrest in 3
(9%), infection in 1 (3%), GvHD 1 (3%). Death was most common
in patients who had open lung biopsies; 66% of open lung biopsies
were followed by death.
Conclusions: A decision to perform a lung biopsy in children post
HSCT is an indicator for poor prognosis. Apart from confirming
malignant progression or rare infectious microorganisms, results
from lung biopsies did not alter their management significantly.78
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APLASTIC ANEMIA
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Current treatment algorithms for pediatric severe aplastic anemia
(SAA) entail up-frontmatched sibling donor (MSD)HCT, or immu-
nosuppressive therapy for those withoutMSD. To assess whether an
immunoablative tolerance-induction regimen for unrelated (MUD)
HCT could be applied to extend up-front application of HCT in
SAA, we retrospectively reviewed our single-institution HCT
experience from 1999-2009 (minimum 1-year follow-up) for SAA
patients using unmanipulated bone marrow grafts from high-resolu-
tion 10/10 HLA-matched donors. Conditioning (cumulative dose)
was cyclophosphamide 200 mg/kg (CTX) 1 rabbit ATG 10 mg/kg
(rATG) for MSD (n 5 9) versus total lymphoid irradiation (TLI,
800 cGy) 1 CTX/rATG for MUD HCT (n 5 5). Immunoprophy-
laxis was cyclosporine A (CSA) and short-course methotrexate for all
patients. Ten of 14 patients were Caucasian, 7 were female, median
age at time of HCT was 14.7 years (range, 4.6 - 19.3), and median
follow-up 3.0 years (range, 1.1 - 10.3). All patients were chronically
platelet and erythrocyte transfusion-dependent at HCT. Mean
CD341 cell dose (MSD: 6.2 64.2  106/kg; MUD: 3.9 62.4 
106/kg) and mean CD31 cell dose (MSD: 28.3 616.2  106/kg;
MUD: 29.4 615.8  106/kg) were not significantly different be-
tween groups. Themajor outcomemeasures were event-free survival
(EFS), engraftment rate, time to engraftment, and cumulative inci-
dence of GVHD within 1 year (CIN of GVHD) for MSD and
MUD cohorts. The EFS and stable engraftment rates were 100%
for MSD and MUD, and time to engraftment of ANC and platelets
was not significantly different between MSD and MUD (p . 0.25).
CIN of acute GVHD was: MSD, Grade I-II: 11%, Grade III-IV:
Oral Presentations S1830%; MUD, Grade I-II: 20%, Grade III-IV: 20%. CIN of chronic
GVHD was: MSD, limited: 11%, extensive: 0%; MUD, limited:
0%, extensive: 0%. Acute GVHDwas treated to resolution with ste-
roid and ongoing CSA therapy, and all patients weaned from immu-
nosuppression by 1 year. There was no significant difference in
regimen-related morbidity or mortality between MSD and MUD
HCT using this risk-adapted modification of conditioning for
MUD HCT. Though in a limited number of patients, our results
suggest that immunomodulatory TLI/CTX/rATG conditioning is
a promising option for MUD HCT in SAA patients. We propose
to examine this in a prospective clinical trial using CTX/rATG for
MSD HCT versus TLI/CTX/rATG for MUD HCT within 3
months of diagnosis for pediatric and young adult patients with idi-
opathic SAA.79
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IN SEVERE
THALASSEMIA PATIENTS IN A SINGLE INSTITUION WITH RELATED
AND UNRELATED DONORS ANDMYELOABLATIVE AND REDUCED INTEN-
SITY REGIMENS
Hongeng, S., Pakakasama, S., Anurathapan, U., Sirachainan, N.,
Songdej, D., Chuansumrit, A. Ramathibodi Hospital, Mahidol University,
Bangkok, Thailand
Recently published reports indicate that the outcome of unrelated
donor hematopoietic stem cell transplantation (HSCT) in patients
with leukemia is comparablewith thatof transplantation from identical
family donors.Wewould like toprove that the outcomesof related and
unrelated transplantation are favorably comparable inchildrenwith se-
vere thalassemia. We reviewed transplant outcome in 87 consecutive
children with severe thalassemia who underwent allogeneic HSCT
the related-donor stem cells (n 5 57) or unrelated-donor stem cells
(n5 30) between September 1992 and July 2010. Analysis of engraft-
ment, frequency of procedure related complications, and thalassemia-
free survival revealed no advantage from use of related-donor stem
cells. The thalassemia-free survival estimate for recipients of related-
donor stem cells was 86% compared with 75% in the unrelated-donor
stemcells group (p50.09).Thepresent studyprovides andevidence to
support the view that it is therefore quite reasonable to consider unre-
lated HSCT as an acceptable therapeutic approach in severe thalasse-
mia, at least for patients who are not fully compliant with conventional
treatment anddonot yet show irreversible severe complications of iron
overload. Moreover, we also have proved that our new reduced inten-
sity conditioning regimen approach can overcome the past poor result
ofHSCT in class 3 lucarelli thalassemia (age$ 10 years) patients (n5
16). Both of the thalassemia free survival and overall survival rates in
this group are 88%.Finally,we have studied the cost utility analysis be-
tweenHSCTandhypertransfusionwith iron chelation therapy in thal-
assemia patients. We can prove that matched related donor
transplantation in thalassemia patients appears to be a cost effective
and affordable treatment for thalassemia patients younger than 10
years of age.80
CLINICAL OUTCOMES OF CHILDREN REQUIRING INTENSIVE CARE FOL-
LOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION
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Clinical outcomes for children admitted to the pediatric intensive
care unit (PICU) are improving with advances in supportive care
strategies. We have reviewed outcomes of children admitted to
PICU after hematopoetic stem cell transplantation (HSCT) to de-
termine the likely outcome for this challenging group of patients.
A retrospective review of our PICU and HSCT databases was per-
formed from July 2004 through June 2009. Over this period, 136
HSCT recipients accounted for 260 PICU admissions. Eighty seven
percent of patients (118/136) had allogeneic HSCT and 13% (17/
136) autologous HSCT. Patients admitted to PICU were atincreased risk of subsequent PICU admission, with an average of 2
PICU admissions per patient. Sixty six percent of transplants (90/
136) were myeloablative, 32% (43/136) were reduced intensity and
2% (2/136) were without conditioning regimen (SCID patients).
Eighty six percent of all allogeneic HSCT (102/118) were from un-
related donors. Eighty two percent of admitted patients (213/260)
survived to PICU discharge. Forty three percent of patients are cur-
rently surviving with a median follow up of 2.9 years (1.1-6.1 yrs).
The median PRISM II score for this cohort was 8 (0-47) days, and
median length of stay was 4 days (1-172 days). Thirty nine percent
of admitted (100/260) required intubation and mechanical ventila-
tion and 58% survived to be discharged from the PICU. Forty two
percent of admitted (109/260) required inotropes or vasopressor
support and 66% of these cases survived to PICU discharge. Four-
teen percent of admitted (36/260) required renal replacement ther-
apy and 50% survived to PICU discharge. The LOS, PRISM II
score, and ventilator days were all significantly lower for patients
who survived to PICUdischarge compared to patients who died dur-
ing their PICU admission [LOS (median 3 vs. 13 days, p\ 0.001),
PRISM II score (median 7 vs. 13, p\0.001), ventilator days (median
5 vs. 12 days, p\ 0.002)]. In summary, we report 82% survival to
PICU discharge, with overall 43% survival at a median follow-up
of nearly 3 years for all HSCT patients admitted to our PICU.
Our data suggest improved survival outcomes for this high risk pa-
tient population compared to historical values.81
BLOOD AND NOT URINE BK VIRAL LOAD PREDICTS OUTCOME IN CHIL-
DREN WITH HEMORRHAGIC CYSTITIS AND VIREMIA AFTER STEM CELL
TRANSPLANTATION
Jodele, S.1, Laskin, B.L.2, Bleesing, J.J.1, Mehta, P.A.1, Filipovich, A.H.1,
Marsh, R.A.1, Myers, K.C.1, Jordan, M.B.1, Kumar, A.1,
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tal Medical Center, Cincinnati, OH; 2Cincinnati Children’s Hospital
Medical Center, Cincinnati, OH
BK virus is a significant cause of hemorrhagic cystitis after stem
cell transplantation (SCT), however, its role in nephropathy post-
SCT is not well studied. We retrospectively evaluated 314 consecu-
tive SCT patients treated at our institution since 2007, when BK
PCR first became clinically available. BK studies were performed
for hematuria or cystitis, not as routine viral screening. Thirty five
SCT patients (11%) had documented hemorrhagic cystitis. Urine
for BK virus was tested in 33/35 patients and was positive in 30
(91%). Average maximum urine viral load was 8 billion copies/
ml, and 73% of patients had a maximum urine viral load . 1 billion
copies/ml. Sixty percent (21/35) of patients with hemorrhagic cystitis
had plasma BK virus tested, and all of them had viremia (n 5 21,
100%). Patients with a maximum plasma viral load of. 10,000 cop-
ies/ml (high viremia; n 5 10) had worse renal outcome and greater
mortality attributed to BK virus compared to patients with #
10,000 copies/ml (low viremia; n 5 11) (table). Specifically, patients
with high viremia had significantly higher creatinine elevation from
pre-SCT baseline. Sixty percent of patients with high plasma viral
load required renal replacement therapy, and half of them developed
end stage renal disease despite BK therapy. Three patients with high
viremia had renal biopsies diagnostic for polyoma virus-associated
nephropathy. Hemorrhagic cystitis was also more severe in the
high viremia group, with half of patients requiring surgical interven-
tions and bladder irrigations for obstructive uropathy. Conversely,
the majority of patients with low viremia had transient elevations
in creatinine and hemorrhagic cystitis that resolved over time. In
summary, BK viremia. 10,000 copies/ml was associated with signif-
icant nephropathy and severe hemorrhagic cystitis following SCT in
our patient cohort. Although majority of SCT patients with hemor-
rhagic cystitis had very high urine viral load, only patients with high
viremia developed nephropathy, end stage renal disease and died
from this infection. Therefore, the degree of viremia, but not viruria,
may identify patients at risk who would benefit from early or aggres-
sive therapy. Future studies should determine optimal monitoring
and treatment protocols for these patients.
